Abbott Laboratories

Abbott Laboratories Beats on EPS, Stock Down 2.6%

Abbott Laboratories reported a better-than-expected EPS, exceeding estimates by nearly 12%. However, the stock fell by 2.6% following the announcement, indicating that investors may have been looking for more comprehensive revenue details or guidance. The lack of additional information from management could have contributed to the stock's decline.